CANNADORF is dedicated to revolutionizing cannabis extraction by prioritizing the production of cannabinoids, terpenes, and flavonoids in a medically safe manner. The company envisions a future where medical-based cannabis drugs are consistently safe and reliable. CANNADORF aims to contribute to this vision by supplying pharmaceutical companies with high-quality and sterile extracts or Active Pharmaceutical Ingredients (APIs) without resorting to synthetic molecules.
The company is actively engaged in the development of a groundbreaking platform technology. This innovative approach involves the cultivation of sterile plant tissue in bioreactors, ensuring the commercial production of premium plant extracts or specific APIs. By adhering to the highest quality standards, CANNADORF strives to meet the diverse needs of pharmaceuticals, nutraceuticals, and cosmeceuticals markets while eliminating the use of synthetic additives.
